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MAP kinaseDual speciﬁcity phosphatases are characterised by their ability to dephosphorylate both phosphotyrosine
and phosphoserine/threonine residues within the one substrate. The aim of this study was to characterise
the phosphatase activity of the atypical dual speciﬁcity phosphatase, DUSP26 on MAP kinases, and to
determine its expression, regulation and function in cancer cells. Overexpression and knockdown of DUSP26
in epithelial cells and in vitro phosphatase assays were used to demonstrate that, contrary to several
published reports, DUSP26 does not act as a dual speciﬁcity phosphatase on ERK, JNK or p38 MAPKs.
However, overexpression of DUSP26 in MCF10A epithelial cells suppressed colony formation and acinar
growth in 3D culture, effects dependent on its phosphatase activity, while knockdown of DUSP26 in
HOSE17.1 cells enhanced colony formation and cellular proliferation. DUSP26mRNA expression was reduced
in neuroblastoma, brain and ovarian cancer cell lines. Consistent with epigenetic silencing of DUSP26,
expression was enhanced by treatment of cells with 5-aza-2-deoxycitidine and trichostatin A, and a CpG
island upstream of the DUSP26 transcriptional start site was variably methylated in cancer cell lines.
Together, these results help to clarify confusion in the literature relating to DUSP26 substrate speciﬁcity and
support recent reports that substrates other than MAPKs are the primary substrates of this phosphatase. In
addition, they indicate that DUSP26 may function as a tumour suppressor in particular cancers.-2-deoxycitidine; DUSP, dual
ase; MAPK, mitogen-activated
een ﬂuorescent protein
erson).
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Dual speciﬁcity phosphatases (DUSPs) comprise a large and
heterogeneous subgroup of the type-1, cysteine-based protein
tyrosine phosphatase (PTP) superfamily [1,2]. The unique feature
that characterises DUSPs is their ability to dephosphorylate both
tyrosine (Tyr) and serine/threonine (Ser/Thr) residues within the
one substrate. The 61 DUSPs can be further divided into subgroups
based on sequence similarity. One of the most extensively character-
ised subgroups comprises the mitogen-activated protein kinase
phosphatases (MKPs). Individual MKPs exhibit substrate selectivity
towards MAPKs ERK, JNK and/or p38 and by dephosphorylating the
TxY activation motif of these kinases act as antagonists of associated
signalling cascades. These phosphatases have been the subject of
several reviews [3–10]. Interestingly, some MKPs are encoded at
chromosomal regions that exhibit loss of heterozygosity, and these
MKPs exhibit reduced expression in particular cancers. These includeDUSP6, DUSP7, DUSP10, DUSP4 and DUSP16, and functional studies
support a role for some of these MKPs as tumour suppressors [11–17].
The largest DUSP subgroup comprises the atypical DUSPs, which
share some characteristics of theMKPs but are most similar to the low
molecular weight phosphatase VH1, present in vaccinia virus [18].
Atypical DUSPs contain the consensus DUSP catalytic domain but lack
the N-terminal CH2/Cdc25 homology domain found in MKPs.
Originally, atypical DUSPs were presumed to play a similar role to
MKPs, as critical regulators of MAPK cascades. Although true for some,
it is now clear that many atypical DUSPs have alternative substrates
and distinct physiological roles (reviewed in refs. [19,20]).
DUSP26 is a 24-kDa atypical DUSP ﬁrst described in 2005 [21].
Since then, although several studies have been published regarding its
MAPK substrate speciﬁcity and biological role [22–28], most are
contradictory and a consensus has yet to emerge. Brieﬂy, DUSP26 has
been reported to function as a p38-speciﬁc phosphatase [21,23], as an
ERK-speciﬁc phosphatase [22] and also as a positive regulator of JNK
and p38 [24]. Another independent study reported that DUSP26 is not
a MAPK phosphatase but instead modulates the PI3K/Akt pathway by
an unknown mechanism [25]. Subsequent studies by the same group
demonstrated that DUSP26 mediated reduced phosphorylation of
ERK5, ERK1/2, Src and Akt in PC12 cells in response to EGF
stimulation, possibly via downregulation of PI3K activity [26].
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DUSP26-interacting partner, and DUSP26 was shown to dephosphor-
ylate kinesin superfamily-associated protein-3 (Kap3), a subunit of
the Kif3a motor complex [27].
The biological roles of DUSP26 also require clariﬁcation. In
anaplastic thyroid carcinoma, DUSP26 over expression enhances
colony formation, while knockdown inhibits cell growth and
increases apoptosis, results consistent with an oncogenic role [23].
Furthermore, in an independent study, overexpression of DUSP26 in
PC12 cells inhibited NGF-induced neurite outgrowth, which suggests
that DUSP26 may help to maintain an undifferentiated phenotype, an
effect also characteristic of an oncogene. However, in contrast,
overexpression of DUSP26 sensitised PC12 cells to cisplatin-induced
apoptosis, consistent with a role as a tumour suppressor [25]. This
hypothesis is supported by two recent studies, one demonstrating
that DUSP26 acts via downregulation of the EGFR [26] and the other
by enhancement of cell–cell adhesion [27].
DUSP26 is highly expressed in neuro-endocrine tissue and is absent
in several human cancer cell lines including those derived from brain
tumours, neuroblastomas [21,24,25], squamous tumours, lymphoma,
colon cancer, non-small cell lung cancer, melanoma, prostatic carcino-
ma, breast carcinomaand cervical carcinoma [21,25]. Loss of expression
also occurs in primary human glioblastoma tumours [27]. Interestingly,
DUSP26 is located at chromosomal region 8p12, which exhibits loss of
heterozygosity in several malignancies, including bladder [17], breast
[29], prostate [14], and ovarian cancers [15,30,31]. These data are
consistent with a role for DUSP26 as a tumour suppressor. However,
DUSP26 may have contrasting roles in speciﬁc cancers, as DUSP26 is
ampliﬁed and overexpressed in anaplastic thyroid carcinoma [23].
It is evident that further work is required to clarify the biochemical
and biological activities of DUSP26. In this paper we present data
regarding the biological function and epigenetic regulation of DUSP26
that support a tumour suppressive role. However, the complete
absence of demonstrable activity against ERK, JNK or p38MAPKs, even
in cells where suppression of proliferation by DUSP26 is observed,
indicates that ‘atypical’ functions must underpin this biological role.
2. Materials and methods
2.1. Cell culture
COS7 (ATCC# CRL-1651), HEK293 cells (ATCC# CRL-1573) and
Phoenix cells (ATCC# SD3444) were cultured in DMEM (Invitrogen,
Mount Waverley, VIC, Australia) supplemented with 10% foetal calf
serum (FCS) (Thermotrace, Noble Park, VIC, Australia), CHO cells
(ATCC# CCL-61) were grown in HamsF12 (Invitrogen) and supple-
mented with 10% FCS. MCF10A-EcoR cells [32] were cultured in
DMEM/F12 (Invitrogen), 5% (v/v) horse serum (Invitrogen), 20 ng/
mL human recombinant EGF (236-EG R&D Systems, Minneapolis, MN,
USA), 0.5 μg/mL hydrocortisone (H-0888 Sigma, Castle Hill, NSW,
Australia), 100 ng/mL cholera toxin (C-8052 Sigma), 10 μg/mL bovine
insulin (I-1882 Sigma), 50 units/mL penicillin G (Invitrogen) and 50
μg/mL streptomycin sulphate (Invitrogen). HOSE17.1 cells [33] were
cultured in 50% M199 media (Invitrogen), 50% MCDB105 media with
L-glutamine and 25 mM HEPES (M6395 Sigma), supplemented with
10% FCS (Thermotrace). Matched RNA and DNA from other cell lines
used for RT-qPCR analysis were obtained from a cell line bank
maintained by G. Lehrbach, Garvan Institute, Australia and RNA and
DNA from brain cancer and neuroblastoma cell lines were kindly
provided by Dr. M. Henderson, Children's Cancer Institute Australia,
Randwick, Australia.
2.2. Antibodies and recombinant proteins
Anti-p-ERK, p-JNK and p-p38 antibodies were purchased from Cell
Signalling Technology, Danvers, MA, USA (#9101, #9251 and #9211,respectively). Anti-ERK, JNK and p38 antibodies were also purchased
from Cell Signalling Technology (#9102, #9252 and #9212, respec-
tively). Anti-GAPDH (6c5) was purchased from Ambion, Austin, TX,
USA (#4300) and anti-V5 antibody was purchased from Invitrogen
(#R960-25). Recombinant active ERK, JNK and p38 were purchased
fromCell Signalling Technology (#7416, #7418 or #7474, respectively).
Recombinant GST-taggedDUSP1was purchased fromUpstate, Saratoga
Springs, NY, USA.
2.3. Expression constructs
Human DUSP26 cDNA in vector pOTB7 was purchased from RZPD
(German Science Centre for Genome Research, Berlin, Germany) and
cloned by PCR into the Gateway entry vector pDONR221 (Invitrogen)
using forward primer 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTTC-
GAAGGAGATAGAACCATGTGCCCTGGTAACTGGCTT-3' and reverse
primer 5'-GGGGACCACTTTGTACAAGAAAGCTGGGTTTCATGCTTCCA-
GACCCTGCCG-3'. DUSP26 cDNA was then cloned by LR recombination
(Invitrogen) into the Gatewaymammalian expression vector pcDNA3.1
(CMV/n-terminal V5), the Gateway prokaryotic expression vector
pDEST15 (T7/N-terminal GST) and the Gateway-converted mamma-
lian retroviral vector pMIG-GFP (pMSCV-IRES-GFP/N-terminal V5),
which enables bi-cistronic expression of the gene of interest with GFP
via an internal ribosomal entry site (IRES) [34]. pMIG-GFP/V5 was
kindly provided by Dr. E. Caldon, Garvan Institute, Australia. Catalyt-
ically inactive DUSP26 (c/s_DUSP26) was generated bymutation of the
critical cysteine at amino acid position 151 to serine (c/s) using two
complimentary oligos with sequence: 5'-GAGGGAAGATCCTGGTGCA-
TAGTGCTGTGGGCGTGAGC-3' and the QuickChange® II Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the
manufacturer's instructions. Expression vectors were sequence veriﬁed
prior to use. pMIG plasmids encoding DUSP2 have been described
previously [35]. The luciferase reporter plasmid pG5E4D38-Lux con-
taining Gal4 elements, and the expression vector pSG/Gal-Elk encoding
a fusion protein of the Gal4 DNA binding domain and the transcativa-
tion domain of ELK-1 were a kind gift of Prof. Peter Shaw (Nottingham)
and have been described previously [36].
2.4. Overexpression and knockdown of DUSP26 in eukaryotic cells
COS7 cells were transfected using Polyfect (Invitrogen) according
to the manufacturer's instructions. To generate DUSP26-containing
retrovirus, the ecotropic packaging cell line Phoenix-EcoR were
transfected 24 h after plating and at 70% conﬂuency, with empty
pMIG-GFP, pMIG_wt_DUSP26 or pMIG_c/s_DUSP26, using Fugene
transfection reagent (Roche, Castle Hill, NSW, Australia) according to
the manufacturer's instructions. The medium was changed after 24 h,
and then the cells were incubated for a further 24 h. Retroviral
supernatants were collected, passed through 0.45 µMMillipore ﬁlters
(Millipore, North Ryde, NSW, Australia), and snap frozen at −80 °C
until use. MCF10A cells were infected with the supernatant in the
presence of Polybrene (Sigma) at 8 µg/mL then expanded for a further
4–7 days prior to sterile sorting by ﬂow cytometry, using the FACS
Vantage SE™ Cell Sorter (BD Biosciences) using FACSDiVa software
version 4.1.2 (BD Biosciences) to obtain a 99.9% GFP-positive
population. SMARTpool™ siRNA reagents speciﬁc for DUSP26 were
purchased from Dharmacon (M-008027-01) (La Fayette, CO, USA).
The non-targeting, RISC free ﬂuorescent tagged Dharmacon siGLO™
was used as a control (D-001600-01-20). 20 nM siRNA was
transfected into HOSE17.1 cells using Lipofectamine 2000 (Invitro-
gen) according to the manufacturer's instructions.
2.5. Generation of puriﬁed recombinant DUSP26 protein
BL21 Plys E. coli (Invitrogen) were transformed with Gateway
pDEST15 vectors encoding GST only, wt_DUSP26 and c/s_DUSP26.
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cultures with 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG)
(Sigma) and 2% w/v glucose for 1.5 h at 37 °C. Bacteria were pelleted
and resuspended in 50 mM Tris–HCl (pH 8.5), 100 mM NaCl, 1 mM
EDTA, 1 mM dithiothreitol (DTT) and the following protease inhibi-
tors: 10 μg/mL aprotinin 10 µg/mL leupeptin and 1 mM PMSF.
Bacterial lysates were sonicated at 4 °C, clariﬁed by centrifugation at
17,500 × g and then incubated with glutathione sepharose 4B beads
(GE Healthcare) overnight at 4 °C. Beads were washed ﬁve times in
lysis buffer and then once in PBS before bound proteins were eluted
using 0.5 M reduced glutathione in 1 M Tris–HCl pH 8.5. Puriﬁed
protein was visualised by Coomassie blue gel staining following SDS-
PAGE and quantiﬁed using a bovine serum albumin (BSA) concen-
tration curve loaded on the same gel. Puriﬁed protein was stored in
small aliquots at −80 °C until use.
2.6. Immunoprecipitation of V5-tagged DUSP26 protein
MCF10A cells stably expressing V5-tagged wt or c/s_DUSP26 and
COS7 cells transiently transfected with vector, wt, or c/s_DUSP26
were lysed in normal lysis buffer containing 50 mM HEPES (pH7.4),
150 mM NaCl, 1% (v/v) Triton X-100, 10% (v/v) glycerol, 1.5 mM
MgCl2, 1 mM EGTA, 10 mM pyrophosphate and 100 mM NaF and
clariﬁed by centrifugation at 17,500 × g. 2.5 mg total protein from
each sample was incubated overnight with approximately 40 μg anti-
V5 antibody covalently coupled to CN-Br beads (A-7345 Sigma). The
CN-Br beads were washed ﬁve times with lysis buffer and twice with
ice cold PBS. Immunoprecipitated protein was visualised using the
anti-V5 antibody and Western blotting as described.
2.7. In vitro phosphatase assays
Puriﬁedwt_DUSP26_GST, c/s_DUSP26_GST or GST only (1 µg) was
assayed in 50 µl of phosphatase buffer; 50 mM imidazole pH7.5,
20 mM p-nitrophenyl phosphate (pNPP) (N4744 Sigma) and 5 mM
DTT at 37 °C for the indicated times (Fig. 2). DUSP1_GST (Upstate)
was used as a positive control. V5-tagged wt_DUSP26 and c/
s_DUSP26 immunoprecipitates from COS7 and MCF10A cells were
similarly assayed. 1/3 of the immunoprecipitated antibody/bead
mixturewas incubatedwith 50 μl phosphatase buffer for the indicated
times (Supplementary Fig. 1). Immunoprecipitates from cells trans-
fected with the empty vector were used as an additional negative
control. The amount of pNPP hydrolysedwasmeasured by absorbance
at 405 nm with a microplate reader. For in vitro phosphatase assays
using puriﬁed recombinant MAPKs, 200 ng ERK, JNK or p38 (#7416,
#7418 and #7474, Cell Signalling) was incubated with 1 µg of puriﬁed
recombinant wt_DUSP26_GST, c/s_DUSP26_GST, GST only (negative
control) or DUSP1_GST (positive control) for 90 min at 37 °C in
10 mM Tris–HCl pH 7, in a total volume of 30 µl.
2.8. Luciferase assays
COS7 cells were co‐transfected with 1.5 µg pcDNA3.1 vector only,
pcDNA3.1 containing wt_DUSP26 or c/s_DUSP26 along with 0.5 µg of
the aforementioned Gal-luc/Gal-ELK reporter system and 0.2 µg of the
β-galactosidase expression vector pCMVβ (Clonetech) using Polyfect
(Quiagen, Doncaster, VIC, Australia) according to the manufacturer's
instructions. One day after transfection the cells were serum starved
for 12–16 h, then stimulated with 100 ng/mL EGF (R&D Systems) for
9 h. Cellswereharvested in Tropix lysis buffer provided by theGalacto-
Star™ (Applied Biosystems) chemiluminescence kit. The lysates were
clariﬁed by centrifugation at 17,500 × g and 5 μl aliquots of the
supernatantswere added to two 96-well plates in duplicate. The lysate
on one plate was incubated for 30 min at room temperature with
100 μl of GalactonStar™ (Applied Biosystems, Scoresby, VIC, Australia)
then production of β-galactosidase was measured using a TopCount™scintillation reader. Luciferase activity was similarly measured using a
TopCount™ scintillation reader immediately following the addition of
50 μl Luciferine (Promega, Annandale, NSW, Australia). Mean lucifer-
ase activity was normalised using the corresponding β-galactosidase
activity and then expressed relative to the untreated control.
2.9. Western blotting
For MAPK activation experiments, HOSE17.1 and COS7 cells were
deprived of serum for 16 h andMCF10A cells were cultured for 16 h in
media deprived of EGF and insulin and containing 0.4% horse serum.
Following starvation cells were treated with either 100 ng/mL EGF for
5 min, 400 mM sorbitol for 3 h or 50 µg/mL anisomycin for 30 min.
Cells were lysed in radioimmunoprecipitation assay buffer (RIPA)
containing 50 mM Tris–HCl pH 7.4, 1% (v/v) NP-40, 0.5% (w/v)
sodium deoxycholate, 0.1% (w/v) sodium dodecyl sulphate (SDS),
137. 5 mM NaCl, 1% (v/v) glycerol, 0.5 mM EDTA, 10 µg/mL aprotinin
(A-1153 Sigma), 10 μg/mL leupeptin hemisulphate (#2167 Auspep,
Melbourne, VIC, Australia), 1 mM phenylmethylsulphonylﬂuoride
(PMSF) (Sigma) and 1 mM of sodium orthovanadate (Sigma).
Equivalent amounts of cell lysates (20–30 µg) were then resolved
by SDS-PAGE and transferred onto PVDF membranes (Millipore).
Membraneswere blocked in 5% (w/v) skimmilk powder in 0.1% (v/v)
Tween 20/Tris-buffered saline and immunoblotted with antibodies as
described above. Speciﬁc proteins were visualised by ECL™ chemilu-
minescence (Perkin-Elmer, Rowville, VIC, Australia). Densitometry
was performed using Image J software (http://rsbweb.nih.gov/ij/).
2.10. Growth of MCF10A cells in 3D, colony formation and proliferation
assays
MCF10A cells were grown on reduced growth factor Matrigel
(354230, BD Biosciences, North Ryde, NSW, Australia) to generate 3D
acini, as previously described [37]. Brieﬂy, a uniform layer of coldMatrigel
was ﬁrst coated onto chamber slides (BD Falcon, Castle Hill, NSW,
Australia) then solidiﬁed at 37 °C. MCF10A cells suspended in growth
medium+2%(v/v)Matrigelwere then laidover theMatrigel at a density
of 1000 cells/mL. 200 µl growth media was added to each chamber and
themediumwas replaced every 4 days. Quantiﬁcation of individual acini
diameter was performed using Image J software. Colony forming assays
were performed by platingMCF10A andHOSE17.1 cells at low density in
triplicate dishes. After 10–14 days the colonies were ﬁxed and stained
using Diff Quick staining protocol according to the manufacturer's
instructions (LabAidsPty, Ltd,Narrabeen,NSW,Australia).Quantiﬁcation
of colony formationwas performed Image J software (http://rsbweb.nih.
gov/ij/). For proliferation assays, cells were plated in triplicate dishes at
low density 24 h after siRNA transfection and maintained in culture for
8 days. Cell counts were performed daily in duplicate.
2.11. Reverse-transcriptase quantitative PCR
cDNA was generated using the Reverse Transcription System
(Promega) according to the manufacturer's instructions. Quantitative
PCR was performed using TaqMan® Gene Expression Assays (Applied
Biosystems) for DUSP26 (Hs00225167_m1) and then normalised to
GAPDH expression (Hs00266705_g1) (or Mm99999915_g1 for
murine cells). Each reaction was repeated in triplicate using 4.5μl
diluted cDNA mixed with 5μl TaqMan® Gene Expression PCR
Universal Master Mix and 0.5μl of the appropriate TaqMan®
Primer/Probe Gene Expression Assay. Relative expression was
determined using Applied Biosystems ABI Prism 7900HT software.
2.12. Epigenetic assays
Cell lineswere treated for 24 hwith 5-aza-2-deoxycitidine (5'AZA)
and/or trichostatin A (TSA), each at 5 µM. Expression of DUSP26
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TaqMan™ primers and probes (Applied Biosystems) as described. For
methylation analysis, 500 ng DNA was bisulphite treated for 6–8 h as
previously described [38]. DNA was then ethanol precipitated and
resuspended in 30 µl water and stored at −20 °C until further use.
Methylation primers were designed to amplify both methylated and
unmethylated bisulphite-converted DNA from the DUSP26 CpG island
which resides 2 kb upstream of the translational start site. Two sets
of primers (A and B) were designed to perform nested PCR (each set
with two outer and one inner primer) to obtain a speciﬁc and
abundant amplicon for direct sequencing. Primers used were
F1A_TTTGTAATTGGTGTAGTTTTGAGAATAT, R2A_CAAAYGCTAYGC-
TAAACCTCAA R3A_ CTATTTCTACCCAAAACAAATTAACAA and F1B_
TTTGTTAATTTGTTTTGGGTAGAAAT, R2B_ TTCTATCCAAAAATA-
CAACCCTAAAC and R3B_ ATYGCCTTTATAACAAATCCATAACTA.
2.13. Statistical analysis
For statistical analyses, a two-sided Student's t-test was used
(Microsoft Excel, WA, USA). Differences were considered to be
statistically signiﬁcant at Pb0.05.
3. Results
3.1. DUSP26 does not act as a dual speciﬁcity phosphatase on MAPKs in
COS7 cells
We sought to determine if DUSP26 could dually dephosphorylate
ERK, JNK or p38 and to clarify multiple conﬂicting reports in theFig. 1. DUSP26 does not dually dephosphorylate MAPKs in COS7 cells. (a–c) Effect of DUSP26
encoding wt DUSP26 or c/s DUSP26 and then stimulated as indicated. Cell lysates were the
Western blot images are representative examples of at least three independent experimen
dephosphorylation. (e)Densitometrywasperformedon theWesternblots fromstimulatedCO
relative to the value for vector-transfected cells, which was arbitrarily set at 1.0. Data represe
error. (f) DUSP26 does not affect nuclearMAPKactivity. An ELK reporterwas co-transfectedwi
galactosidase construct was included as a transfection efﬁciency control. Cells were serum sta
untreated, empty vector-transfected cells. Data represent the mean of four independent expliterature on the MAPK substrate speciﬁcity of DUSP26. First, MAPK
phosphorylation was determined in COS7 cells overexpressing
DUSP26. Following transfection with constructs encoding V5-tagged
wild-type (wt) DUSP26 or the catalytically inactive (c/s) DUSP26
mutant, cells were serum starved and then stimulated with EGF or
sorbitol to activate ERK or JNK and p38 respectively. An equal level of
wt and c/s DUSP26 protein expression was conﬁrmed by Western
blotting with antibodies speciﬁc to the V5 tag (Fig. 1a–c).
Transfection of His–tagged wt DUSP2 or catalytically inactive c/
s_DUSP2 was performed in parallel as a positive control for ERK
dephosphorylation [9,39,40]. Cell lysates were then Western blotted
with phospho-speciﬁc antibodies that recognise ERK, JNK or p38
when these kinases are dually or mono-phosphorylated on the
activation loop TxYmotif. This revealed that despite a clear reduction
in the phosphorylation of ERK in COS7 cells expressing wt DUSP2
(Fig. 1d), DUSP26 does not exhibit DUSP activity towards any of
these MAPKs (Fig. 1a–c). The phosphatase activity of transfected V5-
tagged wt DUSP26 was conﬁrmed using an in vitro assay with p-
nitrophenyl phosphate (pNPP) as a substrate. V5-tagged wt DUSP26
and c/s DUSP26 were immunoprecipitated from COS7 cells and
incubated with pNPP as described in Materials and methods. The
wt_DUSP26 exhibited readily demonstrable phosphatase activity,
but there was no hydrolysis of pNPP by the vector only or c/
s_DUSP26 negative control immunoprecipitates (Supplementary
Fig. 1a, c). In addition, constructs encoding V5-tagged wt DUSP26
or c/s DUSP26 were transfected into HEK293 cells and phospho-
speciﬁc MAPK antibodies were used to demonstrate that DUSP26
does not affect ERK, JNK or p38 phosphorylation in these cells
(Supplementary Fig. 2a–c).on MAPK phosphorylation. COS7 cells were transfected with empty vector or constructs
n blotted with phospho-speciﬁc antibodies against p-ERK (a), p-JNK (b) and p-p38 (c).
ts. (d) A DUSP2/PAC1 construct was transfected to provide a positive control for ERK
S7 cells andMAPKphosphorylationwasnormalised for protein expression andexpressed
nt the mean of at least three independent experiments; error bars indicate the standard
th vector or plasmids encodingwtDUSP26or c/sDUSP26 into COS7 cells. In addition, aβ-
rved and then stimulated with EGF. Normalised luciferase activity is expressed relative to
eriments, each performed in duplicate. Error bars indicate the standard error.
Fig. 2.DUSP26 does not dually dephosphorylate MAPKs in vitro. (a) DUSP26 has intrinsic
phosphatase activity against pNPP. Puriﬁed recombinant GST-tagged wt DUSP26, c/s
DUSP26, GST only or GST-tagged DUSP1 were incubated with pNPP. Error bars represent
standard error of three independent reactions. (b) Activity of DUSP26 against MAPKs in
vitro. Recombinant ERK, JNK or p38 were incubated with puriﬁed GST only, DUSP1-GST,
wt DUSP26-GST or c/s DUSP26-GST. Western blotting with phospho-speciﬁc antibodies
was then used to determine the relative amount of ERK, JNK and p38 phosphorylation.
Western blots shown are representative examples of three independent experiments.
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nuclear expression with some expression in the cytoplasm [21,22,24].
In order to investigate the effect of DUSP26 on the phosphorylation
and activation of nuclear MAPKs, an ELK1 luciferase reporter assay
was used. ELK1 is a transcription factor predominantly downstream of
ERK [41,42], but it is also moderately activated subsequent to JNK and
p38 signalling [43,44]. Plasmids encoding wt DUSP26 or c/s DUSP26
were co-transfected with the ELK1 luciferase reporter construct and a
plasmid encoding β-galactosidase for normalisation of transfection
efﬁciency into COS7 cells. Cells were serum starved and stimulated
with EGF. Upon growth factor stimulation, there was a signiﬁcant
increase in luciferase expression; however, there was no change in
reporter activity in cells transfected with DUSP26, even at high
concentrations of transfected plasmid (Fig. 1f). Similarly, there was no
change in reporter activity in HEK293 or CHO cells transfected with
DUSP26 (Supplementary Fig. 2d and e, respectively). Since this assay
indirectly measures MAPK activity, rather than phosphorylation,
these data indicate that DUSP26 is unlikely to mono-dephosphorylate
MAPKs leading to diminution of their signalling via ELK1.
3.2. DUSP26 does not dually dephosphorylate MAPKs at the TxY motif in
vitro
To determine if DUSP26 could directly dephosphorylate ERK, JNK
or p38 in vitro, GST-tagged wt DUSP26 and c/s DUSP26 were
expressed and puriﬁed from E. coli as described in Materials and
methods. Phosphatase activity of puriﬁed recombinant GST-taggedwt
DUSP26 was conﬁrmed using p-nitrophenyl phosphate (pNPP) as a
substrate. The degree of pNPP hydrolysis by wt DUSP26 was
comparable to that by DUSP1 and there was no hydrolysis of pNPP
by the GST only or c/s DUSP26 controls (Fig. 2a).
Active recombinant MAPKs ERK, JNK and p38 were then incubated
with recombinant wt DUSP26, c/s DUSP26, GST only or DUSP1. Using
phospho-speciﬁc antibodies and Western blotting, we determined
that although DUSP1 could effectively dephosphorylate ERK, JNK and
p38, wt DUSP26 does not exhibit DUSP activity towards these MAPKs
in vitro (Fig. 2b).
3.3. DUSP26 does not dephosphorylate MAPKs in MCF10A or HOSE17.1
cells, despite anti-proliferative effects
DUSP26 expression is absent in several epithelial tumour types
including breast, prostate and colon [21,25]. To investigate the
consequences of DUSP26 overexpression and knockdown in epithelial
cells, colony formation assays were performed using the normal
immortalised breast epithelial cell line MCF10A, stably overexpres-
sing wt DUSP26 or c/s DUSP26, as well as normal immortalised
human ovarian surface epithelial cells HOSE17.1, transfected with
DUSP26-speciﬁc siRNA. Overexpression of DUSP26 in MCF10A cells
was conﬁrmed by Western blotting (Fig. 3a), and RT-qPCR analysis
demonstrated that DUSP26-speciﬁc siRNA reduced DUSP26 mRNA
expression by approximately 75% compared with control siRNA and
mock-transfected control cells (Fig. 3b). Phosphatase activity of stably
expressed wt DUSP26 was conﬁrmed using pNPP as a substrate, as
previously described for COS7 cells (Supplementary Fig. 1b, c).
MCF10A cells overexpressing wt DUSP26 generated fewer colonies
compared with vector only control cells or cells expressing c/s
DUSP26 (Fig. 3c). When grown on an enriched basement membrane,
MCF10A cells form acini with a hollow lumen, modelling develop-
ment of glandular architecture in vivo (described previously in ref.
[37]). To determine the effect of DUSP26 expression on growth of
MCF10A 3D acini, cells stably overexpressing wt DUSP26 or c/s
DUSP26 were cultured on Matrigel™ as described [37]. Acini
overexpressing wt DUSP26 were markedly smaller than those
expressing c/s DUSP26 or the vector only control (Fig. 3d). Consistent
with this result, HOSE17.1 cells generated more colonies whentransfected with DUSP26 siRNA compared with the control siRNA-
transfected cells (Fig. 3e). In addition, the doubling time of DUSP26-
deﬁcient HOSE17.1 cells was signiﬁcantly less than that of the control
siRNA-transfected cells, indicating an increased proliferation rate in
the DUSP26-deﬁcient HOSE17.1 cells (Fig. 3f).
We next sought to determine if the biological effects demonstrated
in MCF10A and HOSE17.1 cells were mediated by dephosphorylation
of MAPKs by DUSP26. MCF10A cells overexpressing DUSP26 or siRNA-
transfected HOSE17.1 cells were serum starved overnight prior to
being stimulated with EGF, sorbitol or anisomycin. Western blotting
indicated that there was no change in the phosphorylation of ERK, JNK
or p38 upon manipulation of DUSP26 expression in either system
(Supplementary Fig. 3).
3.4. Loss of DUSP26 mRNA expression in cancer cell lines
Since DUSP26 suppressed cell proliferation, we characterised the
expression pattern of this phosphatase in cancer cell lines versus
normal cell line or tissue controls, hypothesising that DUSP26 may
exhibit loss of expression consistent with tumour suppressor activity.
DUSP26 mRNA expression was reduced in ovarian cancer cell lines
compared with the immortalised human ovarian surface epithelial
cell line HOSE17.1. Similarly, DUSP26 mRNA expression was much
lower in neuroblastoma cell lines, as compared with normal adrenal
Fig. 3. Effect of DUSP26 overexpression and knockdown in epithelial cells. (a) Western blotting with V5-tag antibody demonstrating overexpression of DUSP26 in MCF10A cells.
(b) RT-qPCR analysis demonstrating knockdown of DUSP26 mRNA in HOSE17.1 cells. Overexpression of DUSP26 in MCF10A cells results in reduced colony forming ability (c) and
smaller acini when cells are grown in 3D (d). Data represent the mean of at least three independent experiments and are expressed relative to the value for control cells, which is
arbitrarily set at 1.0. (e) Transfection of HOSE17.1 cells with DUSP26-speciﬁc siRNA results in an enhanced colony forming ability (e) and increased proliferation rate (f). Error bars
indicate the standard error. Images shown are representative examples of at least three independent experiments.
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lines and one glioblastoma cell line compared with normal brain.
While DUSP26was not expressed in normal mouse astrocytes (Fig. 4),
it remains possible that it is expressed in the neural progenitor cells
thought to be the ‘cell of origin’ for glioblastoma [45].Common mechanisms of gene silencing in cancer include loss of
heterozygosity and epigenetic silencing. In particular, epigenetic
silencing due to hypermethylation of CpG islands located in the
promoter region of tumour suppressor genes is a common and early
event in carcinogenesis [46]. The DUSP26 gene contains a CpG island
Fig. 4. DUSP26 expression in brain tumour, neuroblastoma and ovarian cancer cell
lines. RT-qPCR determined that DUSP26 mRNA expression is reduced in brain cancer
(a), (m=mouse tissue), neuroblastoma (b), and ovarian cancer cell lines (c) compared
with normal controls, which are arbitrarily set at 1.0. Data represent the mean of three
independent reactions; error bars indicate standard error.
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start site (Fig. 5a).
We sought to determine if DUSP26 could be epigenetically
regulated. Treatment of ovarian cancer cell lines with the methyl-
transferase inhibitor (5'AZA) and/or the histone de-acetylase inhib-
itor trichostatin A (TSA) followed by RT-qPCR analysis demonstrated
that DUSP26 expression signiﬁcantly increased in all cell lines after
treatment with 5'AZA and in the majority of cell lines, re-expressionincreased further upon treatment with both 5'AZA and TSA, suggest-
ing that DUSP26 expression can be epigenetically regulated by both
methylation and histone modiﬁcation (Fig. 5b).
To determine if the DUSP26 CpG island is methylated in cancer cell
lines, the DUSP26 promoter associated CpG island was ampliﬁed from
sodium bisulphite-treated cell line DNA using PCR primers that
amplify DNA containing both converted (to uracil, indicating non-
methylated) and non-converted (indicating methylated) cysteine
residues. Direct DNA sequencing of the resulting amplicon deter-
mined that the DUSP26 CpG island was methylated at speciﬁc CpG
sites to a variable extent in the majority of the cancer cell lines
(Fig. 5c). In most of the cell lines, hypermethylation could be
correlated with loss of gene expression (Fig. 4). For example, of the
neuroblastoma cell lines, the highest level of methylation was present
in the cell line SHEP, which displays the least DUSP26 expression and
heavy methylation of the brain cancer cell line SJG2 is consistent with
low to absent expression of DUSP26 (Fig. 4). There was no
methylation in the normal ovarian cell line HOSE17.1 which expresses
DUSP26; however, methylation in the ovarian cancer cell lines was
variable and did not always correspondwith relative expression levels
suggesting that methylation is not the only mechanism by which loss
of DUSP26 expression occurs. Also, consistent with re-expression
following treatment with TSA, it is likely that chromatin modiﬁcation
also plays a role in the epigenetic regulation of DUSP26.
4. Discussion
Despite the growing interest and research focused on DUSP26
since it was ﬁrst characterised in 2005 [21], its functional character-
istics including its biological role and substrate speciﬁcity remain
unclear. Atypical DUSPs have the most varied substrate speciﬁcity of
all the protein tyrosine phosphatases and have been shown to target
alternative protein substrates such as glucokinase (DUSP12) [47],
signal transducer and activator of transcription (STAT) proteins
(DUSP3) [48] and upstream MAPK activators (DUSP22) [49,50].
Atypical DUSPs have also been shown to target non-protein substrates
such as mRNA (DUSP11) [51]. It is becoming clear that, unlike typical
MKPs, atypical DUSPs have a variety of non-MAPK substrates;
however, few generalisations can be made.
The results presented here using cell-based and in vitro assays
indicate that DUSP26 does not act as a dual speciﬁcity phosphatase on
the MAPK proteins ERK, JNK or p38, despite reports to the contrary
that suggest DUSP26 can dephosphorylate p38 [21,52], p38 and ERK
[23], ERK and JNK [22]. While in some contexts DUSP26 appears to
modulate the activity of particular proteins in the MAPK and PI3K
signalling cascades [25,26], the mechanism(s) by which this occurs is
not fully understood. One possibility is that in order to target MAPKs,
DUSP26 requires additional binding partners that act as scaffolds,
tethering DUSP26 to its target(s), and these binding partners are
present or active only in speciﬁc cell types. However, this seems
unlikely given that relatively large amounts of recombinant DUSP26
did not dephosphorylate MAPKs in vitro. Alternatively, DUSP26
phosphatase activity may be regulated by ‘substrate-modulators’
that are also present in a cell-speciﬁc context. It has been shown that
the catalytic activity of some DUSPs can be enhanced upon binding to
their MAPK substrates [53,54]. Consequently, the phosphatase activity
of DUSP26 in vivo may be dependent on the presence of other
proteins that upon binding to the enzyme alter the conformation of
the catalytic domain and direct its substrate speciﬁcity towards
particular MAPKs. Another possibility is that physiological DUSP26
substrates lie upstream of PI3K or MAPKs and affect their activity
indirectly. In this context, the recent study linking DUSP26 with Kif3a
and Kap3 is of interest, since intact microtubule-based transport is
required for NGF-induced MAPK signalling in PC12 cells [55]. Finally,
the effect of DUSP26may differ depending on the speciﬁc hierarchy of
signalling cascades that are activated or on the kinetics of these
Fig. 5. Epigenetic modiﬁcation of DUSP26. (a) Representative scale diagram of DUSP26 genomic sequence. The CpG island is represented as an dotted box 600 bp in length and
starting 100 bp upstream of the transcriptional start site. Exons are represented as white and grey boxes with the translated sequence in grey. (b) DUSP26 expression in ovarian
cancer cell lines before and after treatment with 5'AZA and TSA. Values shown are calculated as an average of three individual reactions. (c) Direct sequencing of bisulphite-
converted DNA across the DUSP26 CpG island identiﬁed speciﬁc CpG sites that were methylated (black boxes) or unmethylated (white boxes).
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versus NGF-induced ERK activation [25,26].
The role DUSPs play in the pathogenesis of various cancers is the
subject of ongoing research. Many DUSPs are encoded at chromo-
somal regions that exhibit loss of heterozygosity and these DUSPs
exhibit reduced expression in particular cancers. Functional studies
support a role for some of these DUSPs as tumour suppressors [11–
17]. Our results are consistent with a functional role for DUSP26 as a
tumour suppressor gene. Speciﬁcally, knockdown of DUSP26 in
HOSE17.1 cells resulted in both an increased ability of these cells to
form colonies and an increase in their proliferation rate. Conversely,
overexpression of DUSP26 in MCF10A cells resulted in a decreased
ability of these cells to form colonies, and the three dimensional acini
that these cells form when grown on an enriched basement
membrane were smaller. Importantly, these effects on cell prolifer-
ation were not mediated via modulation of MAPK pathways,
indicating that DUSP26 must target other substrates involved in
proliferative signalling and/or cell cycle control.
Interestingly, there have been reports suggesting that DUSP26may
have both tumour suppressive [26,27] and oncogenic [23] actions. This
is not the ﬁrst DUSP for which both oncogenic and tumour suppressor
roles have been reported in different cell types. Overexpression ofDUSP1 can result in positive effects on the growth of prostate cancer
[56] but negative effects on the growth of breast cancer cells [57]. The
molecular events that govern the growth, proliferation and survival of
epithelial cells are complex and it is likely that the biological role(s) of
these proteins is cell type and context speciﬁc.
Our results also demonstrate that DUSP26 expression is reduced/
lost in certain cancer cell lines and that this loss of expression is at
least partly due to epigenetic regulation. DUSP26 is located at 8p12, a
chromosomal region previously shown to exhibit loss of heterozy-
gosity in several cancers including bladder [17], breast [29], prostate
[14], and ovarian cancers [15,30,31] implying that tumour suppressor
genes may exist in this region. Analysis of copy number at the DUSP26
locus would determine if genomic deletion occurs in cancers that
show loss of DUSP26 expression. In addition, it will be important to
identify the physiological role of DUSP26 in brain and neuroblastoma
tissue and to determine how its loss perturbs pathways that underpin
tumour progression.
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